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It is our current practice to advise patients with aplastic
anaemia against having influenza vaccination and only to
give other vaccinations if medically indicated.
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ACQUIRED INHIBITOR OF THE INTRINSIC PATHWAY IN A NON-HAEMOPHILIC PATIENT.
CONTROL OF BLEEDING BY RECOMBINANT FACTOR VIIa
The incidence of acquired inhibitors against clotting factors
is rare in previously healthy subjects. Most of them are
related to underlying autoimmune diseases or postpartum
state. We report a case of acquired postpartum bleeding
disorder in a non-haemophilic patient caused by an
inhibitor of the intrinsic pathway that affected factor IX
and the response to treatment with recombinant factor VIIa
(rFVIIa; NovoSeven, Novo Nordisk, Denmark) and predni-
sone.
A 39-year-old woman without previous history of bleed-
ing disorders was admitted as a result of the recent
appearance of skin haematomas in upper and lower
extremities. The patient had delivered her third child
1 month before without significant bleeding, requiring
analgesic treatment with Diclofenac and Aspirin for 10 d.
Initial laboratory data showed normal blood counts and
biochemistry. A plasma coagulation study disclosed a
prolonged activated partial thromboplastin time (aPTT) of
76Æ8 s (ratio 2Æ7) and normal prothrombin time, thrombin
time, fibrinogen level and platelet aggregation. While other
coagulation tests were being carried out, the patient
developed an haemarthrosis at her right elbow with signs
of compartment syndrome.
Clotting factors assay revealed a decreased factor IX
(40 l ⁄ dl), factor XI to be on the lower limit of normal range
(61 l ⁄ dl), and normal factors II, VIII, X, XII, XIII and von
Willebrand factor. No alterations in D-dimer levels were
observed (173 ng ⁄ml), and functional tissue type plasmi-
nogen activator (t-PA) and a2-anti-plasmin were barely
increased. Screening and confirmation tests for lupus
anticoagulant were negative. The aPTT and factor IX levels
were hardly corrected after mixing with control plasma,
indicating the presence of an inhibitor that showed no time
dependence. New mixtures with normal pooled plasma
showed the presence of an inhibitor against factor IX
(2Æ5 Bethesda units).
Treatment with rFVIIa 90 lg ⁄ kg ⁄4 h and prednisone
1Æ5 mg ⁄ kg ⁄24 h was started, resulting in rapid recovery of
factor IX levels. However, the prolongation of aPTT persis-
ted, requiring 15 infusions of rFVIIa to achieve the complete
disappearance of the clinical picture. Table I shows the
patient’s coagulation data at admission and during the
treatment period.
A prospective study of 100 consecutive cases with
prolonged aPTT of unknown aetiology identified the pres-
ence of lupus anticoagulant as the most common cause
(Kitchens, 1988). Alterations of clotting factors in the
intrinsic pathway may also be responsible for the prolon-
gation of the aPTT. In the present report, a postpartum-
acquired inhibitor of the intrinsic pathway affecting factor
IX was detected. The presence of an acquired factor IX
inhibitor is infrequent in haemophilia B patients and is
extremely rare in non-haemophilic patients (Feinstein,
1995). A literature search identified reports of acquired
factor IX inhibitors in a patient with autoimmune disease,
two children and a patient with adenocarcinoma of the
colon.
Bleeding in patients with acquired haemophilia is often
severe, even with low titres of inhibitor, especially during
the first weeks after presentation. However, the presence of
a functional factor IX of 40 l ⁄ dl seems insufficient to cause
such prolongation of the aPTT. This suggests that other
284 Correspondence
 2002 Blackwell Publishing Ltd, British Journal of Haematology 119: 268–288
components of the intrinsic pathway may be affected,
although the determination of other clotting factors showed
no significant alterations.
The aims in the treatment of acquired haemophilia are
control of the haemorrhage and elimination of the auto-
antibody. rFVIIa has proven effective in patients with
alloantibodies and autoantibodies against factor VIII or IX
(Lusher, 1996; Negrier & Hay, 2000). In a NovoSeven
compassionate-use programme in 38 patients with
acquired autoimmune depletion of factor VIII (Hay et al,
1997), a median of 28 doses were administered per
episode. In this case, 15 infusions were required to achieve
a complete clinical response. Remarkably, D-dimer did not
increase significantly during the treatment with rFVIIa.
Persistence of the prolongation of the aPTT, despite
recovery of normal factor IX levels during treatment with
rFVIIa, supports the hypothesis of an inhibitory action
against other factors involved in the intrinsic pathway.
Another explanation could be interference between the
presence of large amounts of factor VIIa and the deter-
mination of factor IX.
Spontaneous disappearance of postpartum-acquired
inhibitors has been reported. However, owing to the severity
of the bleeding, our patient started treatment with predni-
sone, which was maintained with tapered doses for
4 months. After discontinuation of immunosuppresive
therapy, factor IX levels and aPTT remain between normal
ranges.
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THE USE OF RECOMBINANT FACTOR VIIA IN A JEHOVAH’S WITNESS WITH AUTO-IMMUNE
THROMBOCYTOPENIA AND POST-SPLENECTOMY HAEMORRHAGE
We report a 68-year-old female Jehovah’s Witness who
presented with a widespread purpuric rash, blood blisters in
the mouth and a platelet count of 3 · 109 ⁄ l. The blood
count was otherwise normal and bone marrow examination
was consistent with idiopathic auto-immune thrombo-
cytopenia.
Fig 1. (A and B) Serial coagulation tests, haemoglobin and platelet counts.
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She was commenced on prednisolone 60 mg ⁄ d. On d 11
after presentation, the platelet count was only 10 · 109 ⁄ l.
It was confirmed that immunoglobulins were an accept-
able treatment and the patient received a 3 d course of
intravenous immunoglobulin (IVIgG) 25 g ⁄ d. The maxi-
mum platelet count achieved was 31 · 109 ⁄ l. She there-
fore received methyl prednisolone 500 mg i.v. for 3 d, but
the platelet count remained at 14 · 109 ⁄ l. On d 40, the
patient was again given IVIgG, 30 g (0Æ4 g ⁄ kg) daily for
4 d. On d 44, the platelet count had risen to 52 · 109 ⁄ l
with Hb 14Æ4 g ⁄ dl; this platelet count was considered
sufficient to allow splenectomy safely to be performed and
surgery was carried out on d 47. The preoperative
coagulation screen was prothrombin time (PT) 12 s
(normal range, 11–16 s), activated partial thromboplastin
time (APTT) 21 s (22–35 s), fibrinogen 3Æ3 g ⁄ l (1Æ5–
4Æ5 g ⁄ l).
Several hours after splenectomy, her abdomen was found
to be tense and distended; the haemoglobin (Hb) was
8Æ0 g ⁄ dl with platelets 46 · 109 ⁄ l. Gelatin solution
(1500 ml) was given as a non-blood-derived volume
expander and packing inserted to try to contain the bleeding;
aprotinin and tranexamic acid were commenced. The
patient was transferred to the intensive therapy unit
(ITU) with Hb 4Æ5 g ⁄ dl, platelet count 17 · 109 ⁄ l, PT
21 s, APTT 74 s and fibrinogen 1Æ6 g ⁄ l. Cryoprecipitate
was acceptable to the patient and she received 8 units on
two occasions.
Despite continuing life-threatening haemorrhage and in
the face of significant thrombocytopenia and coagulopa-
thy, the patient continued to refuse most plasma products.
Recombinant factor VIIa (Novosen, Novo Nordisk) was
then administered at a dose of 90 lg ⁄ kg. Haemostasis was
achieved, following a single dose, and after two doses
coagulation was normal (PT 11 s, APTT 28 s, fibrinogen
4Æ4 g ⁄ l). A third dose was given after the patient returned
to theatre for removal of packs, when the coagulation
tests deteriorated (see Fig 1A). Factor VIIa has been
reported to promote haemostasis in intractable haemor-
rhage, e.g. following severe trauma (Kenet et al, 1999;
Martinowitz et al, 2001). As it is not derived from blood,
the product is acceptable to Jehovah’s Witnesses (Majum-
dar & Savidge, 1993; Papatheodoridis et al, 1999). Her
thrombocytopenia was managed by continuing steroid
therapy and IVIgG.
Erythropoeitin (10 000 units three times per week) was
commenced on the second day in the ITU (Koestner et al,
1990); vitamin B12, folate and intravenous iron sucrose
were also administered. Further blood loss was minimized
by use of paediatric microsampling. Human or bovine
haemoglobin solutions (natural or recombinant) or per-
fluorocarbons (Marelli, 1994; Doyle, 2001) were found not
to be available outside the context of clinical trials in the
USA and Canada. Hyperbaric O2 was also considered, but it
was thought that the risk of transferring the patient would
outweigh the benefit.
On d 51, the patient suffered an episode of fast atrial
fibrillation and the following day she developed Candida
albicans pneumonia. On d 62, there was evidence of auto-
immune haemolytic anaemia (Hb 6Æ4 g ⁄ dl, positive direct
antiglobulin test, reticulocytes 9Æ1%, lactate dehydrogenase
1488 iu ⁄ l) and further IVIgG was given. By d 72, the
Hb had risen to 10Æ4 g ⁄ dl, with a platelet count of
131 · 109 ⁄ l (Fig 1B). Coagulation was normal as follows:
PT 14 s, APTT 25 s, fibrinogen 4Æ2 g ⁄ l. Erythropoeitin was
reduced to 3000 units three times per week. Inspired
oxygen had been reduced to 40% and it was hoped to
wean her off the ventilator. However, on d 73, the patient
suffered two rectal bleeds, despite a platelet count of
145 · 109 ⁄ l and normal coagulation. She continued to
bleed and her Hb fell to 6Æ5 g ⁄ dl. It was thought that the
patient would not survive total colectomy and she died on
d 75. At post mortem, there was evidence of ischaemic
colitis, a relatively common complication of long-term
treatment on the ITU, as well as adult respiratory distress
syndrome and multiorgan failure.
The treatment of this patient using non-blood methods
resulted in a significantly higher cost. The major drug costs
and an estimate of the costs of keeping the patient on ITU
totalled almost £44 000. The cost of recombinant FVIIa
was £10 250 but, although the final outcome in this
patient was unsuccessful, recombinant factor VIIa clearly
arrested bleeding in the face of life-threatening haemor-
rhage and coagulopathy and would be of value again in
similar circumstances.
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